Condition: Cancer · Sponsor: Lycera Corp.
This is a Phase 1/2A study designed to evaluate the safety and tolerability of increased repeated doses of LYC-55716 in subjects with locally advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Lycera Investigational Site | Huntsville, Alabama, United States | — |
| Lycera Investigational Site | Sacramento, California, United States | — |
| Lycera Investigational Site | Washington D.C., District of Columbia, United States | — |
| Lycera Investigational Site | Sarasota, Florida, United States | — |
| Lycera Investigational Site | Atlanta, Georgia, United States | — |
| Lycera Investigational Site | Augusta, Georgia, United States | — |
| Lycera Investigational Site | Chicago, Illinois, United States | — |
| Lycera Investigational Site | Saint Cloud, Minnesota, United States | — |
| Lycera Investigational Site | Omaha, Nebraska, United States | — |
| Lycera Investigational Site | New York, New York, United States | — |
| Lycera Investigational Site | Durham, North Carolina, United States | — |
| Lycera Investigational Site | Oklahoma City, Oklahoma, United States | — |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02929862